1. Why is Nuclera changing its CEO now?
Michael has led Nuclera to this stage as a founder, scientific leader, and company builder. As the company moves into its next stage of commercial growth, Michael and the Board agree that this is the right time to bring in a CEO with deep life-science tools experience and a strong commercial operating background. Carl brings that experience, while Michael will continue to play a central role as Chief Scientific and Business Officer, focusing on scientific strategy, market development, and strategic partnerships.
2. Why is Carl Raimond the right person to lead Nuclera at this stage of its growth?
Carl brings deep life-science tools experience and a strong commercial operating background. He has worked across large organizations such as PerkinElmer and Agilent Technologies, as well as a high-growth company environment at Olink Proteomics, where he played a leading commercial role in the company’s growth and helped lead it through its $3.1 billion acquisition by Thermo Fisher Scientific. That combination of scaling experience, commercial discipline, and customer adoption focus is exactly what Nuclera needs at this stage.
3. How does this leadership change affect Nuclera’s plans for future fundraising?
This leadership transition does not change Nuclera’s financing posture. The company is well-capitalized, and the leadership team is focused on executing its product strategy, expanding customer adoption, and building sustainable commercial growth. As a private company, we do not comment on future financing plans.
4. Why should the market view this as an evolution of Nuclera rather than a change in direction?
This is an evolution, not a reset. Nuclera’s mission, technology foundation, and priority workflows remain consistent. Carl is joining to strengthen commercial execution and customer adoption, while Michael remains a key executive leader as Chief Scientific and Business Officer, maintaining continuity in scientific direction.
5. Is Nuclera targeting profitability, further fundraising or an exit as part of its longer-term plans?
Nuclera’s focus is on building a durable, commercially successful business by creating meaningful value for recombinant protein customers. As a private company, we do not comment on specific financing plans, profitability timelines, or strategic transaction plans. The leadership team is focused on execution, customer adoption, and long-term value creation.
6. What does Michael Chen’s transition to Chief Scientific and Business Officer mean for his role and responsibilities?
As Chief Scientific and Business Officer, Michael will focus on scientific strategy, market development and strategic partnerships, working closely with Carl as the Company enters its next phase of growth whilst maintaining continuity in Nuclera’s scientific direction.
7. You describe this as Nuclera’s “next phase of growth” — what does that mean in practical terms?
In practical terms, it means turning Nuclera’s decade of scientific and technology development in cell-free protein synthesis and digital microfluidics into commercial traction: deeper adoption of eProtein Discovery™ among existing customers, growth of our antibody and membrane protein service and product lines, and a sharper focus on the workflows where customers see value fastest.
8. Does Carl’s appointment represent a change in Nuclera’s strategy or direction?
Carl’s appointment is not being announced as a strategic reset. Nuclera’s mission and core technology foundation remain consistent, and Michael will continue to provide scientific continuity as Chief Scientific and Business Officer. As CEO, Carl will work with the Board and leadership team to assess priorities, sharpen execution, and ensure the company is focused on the opportunities with the greatest customer and commercial impact.
9. How will Carl’s experience at Olink and Thermo Fisher help Nuclera achieve its next stage of growth?
Carl’s experience is highly relevant because Nuclera is entering a stage where commercial execution, customer adoption, and operating discipline are increasingly important. At Olink, he helped scale a differentiated proteomics technology into a high-growth life-science tools business that was acquired by Thermo Fisher Scientific. He also brings experience from larger organizations, including Thermo Fisher, PerkinElmer, and Agilent Technologies. That combination gives him the perspective to help Nuclera translate its technology platform into repeatable commercial success.
10. What differentiates Nuclera’s technology and capabilities from other companies working in cell-free protein synthesis and protein production?
Nuclera’s differentiation comes from combining cell-free protein synthesis with proprietary digital microfluidics to make difficult proteins faster and easier to access. Today, that supports two priority workflow areas: full-length IgG antibody binding triage, and rapid membrane protein prototyping, delivered both as a service and in-house through eProtein Discovery™. We are also advancing early partner work toward customer-site antibody screening workflows, extending cell-free expression and binding triage closer to AI-enabled discovery teams.
11. What are Nuclera’s key priorities over the next 12–24 months?
- Expand high-value antibody and membrane protein services and workflows.
- Continue early partner work exploring customer-site antibody screening workflows.
- Grow customer adoption of eProtein Discovery™ across existing and new accounts.
- Strengthen commercial execution around the applications where customers see value fastest.
12. Should the market expect any significant changes to Nuclera’s product roadmap, commercial strategy or investment plans as a result of this leadership transition?
No significant changes are being announced as part of this leadership transition. Nuclera remains focused on supporting existing customers, executing its strategy, and expanding adoption across priority workflows. Carl will work with the Board and leadership team to sharpen priorities and commercial execution, while Michael’s continued role provides continuity in scientific strategy.